INmune Bio upgraded to Buy from Neutral at Lucid Capital
Lucid Capital upgraded INmune Bio (INMB) to Buy from Neutral with a price target of $9, up from $2. The firm is now factoring into the model the company’s CORDStrom therapy for recessive dystrophic epidermolysis bullosa. Lucid cites the expanded scope of value drivers across INmune’s pipeline for the upgrade.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Read More on INMB:
- Inmune Bio Completes Early INKmune Trial in Advanced Prostate Cancer: What Investors Should Watch Next
- INmune Bio Highlights CORDStrom RDEB Program and IP Strength
- INmune Bio Advances XPro Toward Registrational Alzheimer’s Study
- INmune Bio to Present New CORDStrom Phase III Data
- INmune Bio Advances CORDStrom Toward Rare Disease Commercialization
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
British Pound seems vulnerable near 1.3300 vs USD on Iran tensions, UK political turmoil
Unusual Options Activity: DHI, TSM and Others Attract Market Bets, DHI V/OI Ratio Reaches 102.7
WTI advances to two-week top, eyes $102.50 as rising Iran tensions stoke supply fears
PBOC sets USD/CNY reference rate at 6.8435 vs. 6.8415 previous
Trending news
MoreCrypto prices
More
